Blank Preparation.

Phase 3Small molecule

FFujian Shengdi Pharmaceutical Co., Ltd.

Blank Preparation. is one of 2 small molecule programs targeting Postsurgical Pain Management. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postsurgical Pain ManagementRecruiting

Postsurgical Pain ManagementPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Postsurgical Pain Management

#DrugCompanyPhaseTrials

TLC590

TTLC Biopharmaceuticals, Inc.

Phase 3

3 2

Blank Preparation.

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nausea and vomiting1 trial

A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults

Completed·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT06475846·235 enrolled

Postsurgical Pain Management1 trial

A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery

Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2/3·NCT07185594·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Blank Preparation.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blank Preparation. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blank Preparation.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Shengdi Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFujian Shengdi Pharmaceutical Co., Ltd.

Blank Preparation.

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nausea and vomiting1 trial

Postsurgical Pain Management1 trial

References

Drug Info

Quick Facts

Related News